Claims for Patent: 4,277,479

Summary for Patent: 4,277,479

Title:	Tetrazolylalkoxycarbostyril derivatives and pharmaceutical compositions containing them
Abstract:	Novel tetrazolylalkoxycarbostyril derivative of the formula (I): (I) wherein R1 is a hydrogen atom, a lower alkyl group, a low alkenyl group, a lower alkanoyl group, a benzoyl group or phenylalkyl group; R2 is a hydrogen atom, a lower alkyl group or a group of the formula R3 is a lower alkyl group, a cycloalkyl group, a cycloalkylalkyl group, a phenyl group or a phenylalkyl group; A is a lower alkylene group; the carbon-carbon bond between 3- and 4-positions in the carbostyril skeleton is either single or double bond; and the substituted position of a group of the formula, in the carbostyril skeleton is either 4-, 5-, 6-, 7- or 8-position provided that the only one such group of the formula can be substituted in the whole carbostyril skeleton, thus when R2 in 4-position is a group of the formula then 5-, 6-, 7- or 8-position will have no such substituted group; furthermore, the phenyl group in the above-mentioned benzoyl group, phenylalkyl group or phenyl group may have substituted group(s). The above-mentioned novel tetrazolylalkoxycarbostyril derivatives have pharmacological activities such as platelet aggregation inhibitory action, antiinflammatory action, antiulcer action, vasodilatory action and phosphodiesterase inhibitory action and are useful as anti-thrombosis agent, cerebral blood flow improving agent, antiinflammatory agent, antiulcer agent, anti-hypertensive agent and anti-asthmatic agent.
Inventor(s):	Takao Nishi, Kazuyuki Nakagawa
Assignee:	Otsuka Pharmaceutical Co Ltd
Application Number:	US06/070,710
Patent Claims:	1. A compound of the general formula, ##STR15## wherein R1 is a hydrogen atom, a lower alkyl group, a lower alkenyl group, a lower alkanoyl group, a benzoyl group or a phenyl-C1-4 alkyl group; R2 is a hydrogen atom, a lower alkyl group or a group of the formula ##STR16## R3 is a lower alkyl group, a C3-8 cycloalkyl group, a C3-8 cycloalkyl-C1-4 alkyl group, a phenyl group or a phenyl-C1-4 alkyl group; A is a lower alkylene group; the carbon-carbon bond between 3- and 4-positions in the carbostyril skeleton is either single or double bond; and the substituted position of the group represented by the formula, ##STR17## in the carbostyril skeleton is either 4-, 5-, 6-, 7- or 8-position provided that only one such group of the formula can be substituted in the whole carbostyril skeleton, thus when R2 in 4-position is ##STR18## then 5-, 6-, 7- or 8-position will have no such substituted group; furthermore, the phenyl group in the above-mentioned benzoyl group, phenyl-C1-4 alkyl group or phenyl group may have substituted group(s) selected from the group consisting of lower alkoxy, lower alkyl, halogen, di-lower alkylamino, nitro, and lower alkenedioxy. 2. A compound of the general formula (I) according to claim 1, wherein the substituted position of the group of the formula ##STR19## is 5-position of the carbostyril skeleton. 3. A compound of the general formula (I) according to claim 2, wherein R3 is a C3-8 cycloalkyl group or a C3-8 cycloalkyl-C1-4 alkyl group. 4. A compound of the general formula (I) according to claim 2, wherein R3 is a phenyl-C1-4 alkyl group which may have substituted group(s) selected from the group consisting of lower alkoxy, lower alkyl, halogen, di-lower alkylamino, nitro, and lower alkenedioxy, a phenyl group which may have substituted group(s) selected from the group consisting of lower alkoxy, lower alkyl, halogen, di-lower alkylamino, nitro, and lower alkenedioxy or a lower alkyl group. 5. A compound of the general formula (I) according to claim 1, wherein the substituted position of the group of the formula ##STR20## is 6-position of the carbostyril skeleton. 6. A compound of the general formula (I) according to claim 5, wherein R3 is a C3-8 cycloalkyl group or a C3-8 cycloalkyl-C1-4 alkyl group. 7. A compound of the general formula (I) according to claim 5, where R3 is a phenyl-C1-4 alkyl group which may have substituted group(s) selected from the group consisting of lower alkoxy, lower alkyl, halogen, di-lower alkylamino, nitro, and lower alkenedioxy, a phenyl group which may have substituted group(s) selected from the group consisting of lower alkoxy, lower alkyl, halogen, di-lower alkylamino, nitro, and lower alkenedioxy, or a lower alkyl group. 8. A compound of the general formula (I) according to claim 1, wherein the substituted position of the group of the formula ##STR21## is 4-, 7- or 8-position of the carbostyril skeleton. 9. A compound of the general formula (I) according to claim 8, wherein R3 is a C3-8 cycloalkyl group or a C3-8 cycloalkyl-C1-4 alkyl group. 10. A compound of the general formula (I) according to claim 8, where R3 is a phenyl-C1-4 alkyl group which may have substituted group(s) selected from the group consisting of lower alkoxy, lower alkyl, halogen, di-lower alkylamino, nitro, and lower alkenedioxy, a phenyl group which may have substituted group(s) selected from the group consisting of lower alkoxy, lower alkyl, halogen, di-lower alkylamino, nitro, and lower alkenedioxy or a lower alkyl group. 11. 6-[3-(1-Cyclohexyltetrazol-5-yl)propoxy]carbostyril. 12. 6-[3-(1-Benzyltetrazol-5-yl)propoxy]carbostyril. 13. 5-[3-(1-Cyclohexyltetrazol-5-yl)propoxy]-3,4-dihydrocarbostyril. 14. 6-[3-(1-Phenyltetrazol-5-yl)propoxy]carbostyril. 15. 4-Methyl-6-[3-(1-cyclohexyltetrazol-5-yl)-propoxy]carbostyril. 16. 6-[3-(1-Cyclohexylmethyltetrazol-5-yl)propoxy]-carbostyril. 17. 6-[3-(1-Cyclooctyltetrazol-5-yl)propoxy]-carbostyril. 18. 6-[3-(1-Cyclopentyltetrazol-5-yl)propoxy]-carbostyril. 19. 6-[4-(1-Cyclohexyltetrazol-5-yl)butoxy]carbostyril. 20. 6-[3-(1-Cyclohexyltetrazol-5-yl)propoxy]-3,4-dihydrocarbostyril. 21. 6-[3-(1-Cyclohexylmethyltetrazol-5-yl)propoxy]-3,4-dihydrocarbostyril. 22. 7-[3-(1-Cyclohexyltetrazol-5-yl)propoxy]-3,4-dihydrocarbostyril. 23. 8-[3-(1-Cyclohexyltetrazol-5-yl)propoxy]-3,4-dihydrocarbostyril. 24. 4-[3-(1-Cyclohexyltetrazol-5-yl)propoxy]-carbostyril. 25. A platelet aggregation inhibitor composition containing as an active ingredient a pharmacologically effective amount of a compound of the formula (I) of claim 1 and a pharmaceutically acceptable carrier. 26. A phosphodiesterase inhibitor composition containing as an active ingredient a pharmacologically effective amount of a compound of the formula (I) of claim 1 and a pharmaceutically acceptable carrier. 27. A cerebral blood flow improver composition containing as an active ingredient a pharmacologically effective amount of a compound of the formula (I) of claim 1 and a pharmaceutically acceptable carrier. 28. An anti-hypertensive agent composition containing as an active ingredient a pharmacologically effective amount of a compound of the formula (I) of claim 1 and a pharmaceutically acceptable carrier.